Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
To determine whether the combination of ezetimibe and simvastatin improves biomarkers of
atherothrombosis compared to simvastatin alone in patients with the metabolic syndrome.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Simvastatin